Profiel
Irene Pleasure is currently the Vice President-Intellectual Property at Achaogen, Inc. Prior to this, she worked at Genentech, Inc. as a Senior Associate General Counsel from 2003 to 2017.
She also held positions at Roche Holding AG and Vir Biotechnology, Inc. as a Member and Senior Vice President & General Counsel, respectively.
Ms. Pleasure holds a doctorate degree from Thomas Jefferson University, an undergraduate degree from the University of Pennsylvania, and a graduate degree from The Santa Clara University School of Law.
Eerdere bekende functies van Irene Pleasure
| Bedrijven | Functie | Einde |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Algemeen Adviseur | 01-03-2022 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Algemeen Adviseur | 01-04-2017 |
| ROCHE HOLDING AG | Corporate Officer/Principal | - |
| ACHAOGEN | Corporate Officer/Principal | - |
Opleiding van Irene Pleasure
| University of Pennsylvania | Undergraduate Degree |
| Thomas Jefferson University | Doctorate Degree |
| The Santa Clara University School of Law | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| VIR BIOTECHNOLOGY, INC. | Health Technology |
| ROCHE HOLDING AG | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
